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Abstract
Inflammasomes coordinate the maturation of IL-1β and IL-18 in response to danger signals.
They are vital for maintenance of intestinal homeostasis and have been linked to chronic in-
testinal inflammation in humans. Probiotics have been advocated as treatment in intestinal
inflammation. So far, no study has investigated the role of the inflammasome in canine
chronic enteropathy (CE). In this study the intestinal expression of inflammasome compo-
nents was assessed in CE dogs compared to controls, when treated with probiotic Entero-
coccus faecium (EF) ex-vivo and in-vivo. RNA extraction from endoscopic biopsies and
reverse-transcriptase quantitative PCR was performed for NLRP3, casp-1, IL-1β and IL-18.
Immunohistochemistry was performed to investigate protein expression in tissues. Gene
expression of casp-1 and NLRP3 was lower in CE samples than controls. Ex-vivo treatment
with EF reduced NLRP3 expression in control samples. Treatment of CE dogs with EF
alongside dietary intervention had no effect on gene expression. In contrast, IL-1β protein
expression in CE decreased with dietary treatment (but not with probiotics). The results of
this study suggest that the inflammasome or its components may be partially involved in the
inflammatory process seen in CE, but distinct from intestinal inflammation in humans.
Introduction
In dogs, chronic enteropathies (CE) are a group of disorders of unknown cause associated with
chronic gastrointestinal (GI) symptoms of unknown cause [1]. There are parallels to human In-
flammatory Bowel Disease (IBD), as both are considered chronic immune-mediated inflamma-
tory diseases of the GI tract that result from a dysregulated mucosal immune response to
bacterial antigens [2]. Inflammasomes are found in a wide range of cell types including macro-
phages, dendritic cells and intestinal epithelial cells [3]. The inflammasome complex is composed
of multiple cytosolic proteins, including NOD-like receptors (NLRs), the adaptor protein ASC
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(apoptosis-associated speck-like protein containing a CARD domain) and caspase-1 (casp-1).
NLRs bind to bacterial constituents, purine-like compounds, and other substrates [4–7]. They
are defined by their N-terminal region, which most commonly holds a caspase-recruitment do-
main (CARD) or a pyrin domain (PYD) [8]. Depending of the presence of these domains, the re-
ceptors are classified into either NLRCs (NLR with CARD) or NLRPs (NLR with PYD).
Activation of both types of receptors results in casp-1 activation, which cleaves the precursors of
the inflammatory cytokines Interleukin (IL)-1β and IL-18 into their active proteins [7], whereas
IL-33 becomes inactivated [9]. Secretion of the bioactive cytokines enhances antimicrobial func-
tions of innate immune cells, promotes protection against intracellular pathogens [10, 11], and
can elicit pyroptosis (inflammatory cell death) of the inflammasome-activated cell [12].
Results of several studies point towards a potential role of inflammasomes in the develop-
ment of chronic intestinal inflammation. In human patients with IBD, both IL-1β and IL-18
are up-regulated on the mRNA and protein level in the colon [13–16]. Furthermore, genetic
variations of IL-18 and NLRP3 have been associated with the development of human Crohn’s
disease [17, 18], whereas an involvement of the NLRP3 inflammasome in the development of
ulcerative colitis (UC) is still a matter of debate. NLRs, especially NLRP3 play a dual and some-
what contradictory role in the intestine: NLRP3 seems to be partly responsible for maintaining
mucosal barrier homeostasis as it protects from epithelial injury, as some studies have shown
that mice lacking NLRP3 are more susceptible to develop chemically induced colitis, similar to
mice lacking ASC or casp-1. However, other studies showed that colitis in rodents is actually
mediated by NLRP3 [3, 19, 20]. As most of the functions of NLRP3 seem to be driven by mi-
crobial signals from the commensal microbiota, differential functions of the inflammasomes
depending on distinct microbial signalling is possible [21, 22].
Because NLRs recognise bacterial components, they have an important function in the
cross-talk between the intestinal microbiota and the local immune system. Hence, the applica-
tion of “beneficial” microbes might provide an opportunity to improve inflammatory intestinal
conditions, such as CE or IBD. These probiotics have been defined by the World Health Orga-
nisation to be “live microbes which, when administered in adequate amounts, confer a health
benefit to the host” [23]. They are frequently commensal bacteria, but can also be sourced from
fermented foods or the environment [24]. Several studies have shown that probiotics can influ-
ence key biological signalling pathways of inflammation, which can be specific to an individual
probiotic strain, including strains of the same bacterial species [25].
There is not much known about the function and expression of inflammasomes in the ca-
nine gut, and their role in canine CE is unexplored. So far, one study investigated IL-1β and the
IL-1β receptor antagonist in canine IBD tissues compared to tissues from healthy control ani-
mals and found an altered ratio of those proteins in samples from IBD cases. However, there
was no absolute change in IL-1βmRNA or protein in this study, which possibly indicates an in-
crease in inflammatory signals driven by IL-1β in canine IBD [26].
The purpose of the present study was to examine the role of different components and out-
puts of the inflammasome (NLRs, casp-1, IL-1β, IL-18) in canine CE and determine if the ex-
pression of these components is influenced by the ex-vivo and in-vivo treatment with a
probiotic bacterial strain.
Results
NLRP3, but not NLRP1 or NLRC4 are expressed in healthy canine
intestinal tissues
Initially, the expression of several NLRs involved in formation of inflammasomes was exam-
ined in canine intestinal tissue by standard PCR. For this, cDNA derived from the duodenum
Effect of Probiotics on the Canine Intestinal Inflammasome
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and colon of 7 healthy Beagle dogs and 6 dogs with CE was used (their signalment can be
found in Table 1). No mRNA transcripts for NLRP1 or NLRC4 were detectable in any sample
(Fig. 1); despite the fact that gDNA for these genes was readily detectable (Fig. 2). In contrast,
mRNA transcripts for NLRP3 were detected in intestinal cDNA samples from some healthy
dogs (Fig. 1). Based on these initial findings, it was decided to quantify mRNA expression of
NLRP3 together with IL-1β, IL-18 and casp-1 in a selection of intestinal samples taken from
healthy and diseased dogs.
Expression of the NLRP3 and caspase-1 mRNA is reduced in samples
from dogs with chronic enteropathy
Having established which NLRs and down-stream molecules can be detected by RT-PCR, we
next assessed the expression of mRNA transcripts for NLRP3, IL-1β, IL-18 and casp-1 by
qPCR in duodenal samples taken from 18 healthy and 22 dogs with CE (their signalment and
clinical data can be found in Table 1). Expression levels for casp-1 and NLRP3 mRNA were sig-
nificantly lower in samples form dogs with CE compared to healthy controls (Fig. 3). In con-
trast, there was no significant difference in mRNA expression levels for IL-1β and IL-18
between the groups.
Ex-vivo stimulation with probiotic Enterococcus faecium increases
caspase-1 mRNA expression compared to other TLR ligands, but has
no influence on other inflammasome genes
Having established differences in NLRs expression in biopsies from healthy dogs and dogs with
CE, we next wanted to know whether ex-vivo stimulation of intestinal biopsies with EF impacts
on NLR mRNA expression levels. To do so, fresh endoscopic duodenal biopsies were taken
from 17 dogs with CE and 11 healthy controls (their signalment can be found in Table 1). Stim-
ulation included culturing the biopsies in cell culture medium and respective additives (TLR-li-
gands, live EF or PBS as a control) for 5 hours at standard culture conditions (see below). The
stimulation induced significant changes in expression of some inflammasome-related genes
(Fig. 4). IL-18 mRNA expression was significantly down-regulated when intestinal samples
from CE dogs were stimulated with LPS or flagellin compared to mRNA expression levels in
samples from controls. Casp-1 mRNA expression was significantly increased upon stimulation
with EF independent of the disease-status when compared to stimulation with single TLR li-
gands, but was not different compared to PBS. mRNA expression of IL-1β and NLRP3 was not
significantly different with regards to disease status or across different treatments in the full
mixed-model analysis.
IL-1β protein production is increased in inflamed duodenal tissue and
reduces with treatment
We next assessed the presence and localisation of IL-1β protein (as one of the main “outputs”
of inflammasome activation) in canine duodenal samples by immunohistochemistry (IHC). In
detail, there were samples from healthy dogs (n = 12), archived samples from CE dogs (n = 11;
these dogs histologically had lymphoplasmacytic or mixed enteritis and were diagnosed with
idiopathic IBD) and samples from the prospective clinical trial mentioned below (these dogs
were all diagnosed with food-responsive chronic enteropathy; 9 samples from visit 1/ before di-
etary intervention; 8 samples from visit 2/ after 6 weeks of hydrolyzed protein diet). Quantita-
tive assessment of positively staining cells (Fig. 5) revealed that the total count of IL-1β
producing cells was subjectively increased in CE dogs compared to controls (although not
Effect of Probiotics on the Canine Intestinal Inflammasome
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Table 1. Signalment of healthy control dogs (C) and dogs with chronic enteropathy (CE) fromwhich duodenal (duo) and colonic (col) samples
were used for assessing gene and protein expression of inflammasome-components.
sample ID breed age (months) gender sample type used for
CE1 Labrador 29 f duo baseline gene expression
CE2 Bichon Frise 87 mn duo baseline gene expression
CE3 Boxer 27 mn duo baseline gene expression
CE4 Weimaraner 71 fn duo baseline gene expression
CE5 Golden Retriever 14 f duo baseline gene expression
CE6 Cross breed 50 mn duo baseline gene expression
CE7 CKCS 64 f duo comparison healthy to CE, IHC
CE8 Golden Retriever 139 m duo comparison healthy to CE, IHC
CE9 Rottweiler 66 m duo comparison healthy to CE, IHC
CE10 Tibetan Spaniel 85 m duo comparison healthy to CE, IHC
CE11 English Pointer 156 fn duo comparison healthy to CE, IHC
CE12 Yorkshire Terrier 24 mn duo comparison healthy to CE, IHC
CE13 Cocker Spaniel 129 fn duo comparison healthy to CE, IHC
CE14 Golden Retriever 108 mn duo comparison healthy to CE, IHC
CE15 Rottweiler 30 m duo comparison healthy to CE, IHC
CE16 Gross breed 11 m duo comparison healthy to CE, IHC
CE17 Boxer 159 mn duo comparison healthy to CE, IHC
CE18 Labrador 48 f duo comparison healthy to CE
CE19 CKCS 12 fn duo comparison healthy to CE
CE20 Weimaraner 131 fn duo comparison healthy to CE
CE21 CKCS 131 fn duo comparison healthy to CE
CE22 Cross breed 73 mn duo comparison healthy to CE
CE23 Basset Hound 41 m duo comparison healthy to CE
CE24 Yorkshire Terrier 20 m duo comparison healthy to CE
CE25 Cross breed 76 m duo comparison healthy to CE
CE26 Rhodesian Ridgeback 139 fn duo comparison healthy to CE
CE27 Cairn Terrier 89 fn duo comparison healthy to CE
CE28 Staffordshire 76 m duo comparison healthy to CE
CE29 Labrador 33 m duo, col clinical trial, ex-vivo, IHC
CE30 Standard Poodle 67 m duo, col clinical trial, ex-vivo, IHC
CE31 Labrador 46 fn duo, col clinical trial, ex-vivo, IHC
CE32 Labrador 13 mn duo, col clinical trial, ex-vivo, IHC
CE33 Miniature Schnauzer 78 m duo, col clinical trial, ex-vivo, IHC
CE34 Golden Retriever 24 m duo, col clinical trial, ex-vivo, IHC
CE35 English Setter 18 mn duo, col clinical trial, ex-vivo, IHC
CE36 Labrador 49 fn duo, col clinical trial, ex-vivo, IHC
CE37 Golden Retriever 66 fn duo, col clinical trial, ex-vivo, IHC
CE38 Labrador 29 m duo, col clinical trial, ex-vivo
CE39 Bracco Italiano 12 m duo, col clinical trial, ex-vivo
CE40 Labrador 84 fn duo, col clinical trial, ex-vivo
CE 41 Cockapoo 39 fn duo ex-vivo
CE42 Labrador 98 fn duo ex-vivo
CE43 Golden Retriever 55 fn duo ex-vivo
CE44 Boxer 40 mn duo ex-vivo
CE45 Golden Retriever 8 mn duo ex-vivo
C1 Beagle 131 m duo baseline gene expression
(Continued)
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significant), and that the number of positive cells decreased significantly after treatment in the
CE dogs (Fig. 6). Interestingly, this was not reflected by an increase of IL-1β positive cells in the
villi, but mostly carried by an increase in positive cells in the lamina propria, which did not en-
tirely return to baseline values after treatment (Fig. 6).
Table 1. (Continued)
sample ID breed age (months) gender sample type used for
C2 Beagle 49 m duo baseline gene expression
C3 Beagle 31 f duo baseline gene expression
C4 Beagle 43 f duo baseline gene expression
C5 Beagle 56 f duo baseline gene expression
C6 Beagle 17 m duo baseline gene expression
C7 Beagle 43 f duo baseline gene expression
C8 Greyhound 61 fn duo comparison healthy to CE
C9 Greyhound 48 fn duo comparison healthy to CE
C10 Greyhound 72 m duo comparison healthy to CE
C11 Greyhound 48 f duo comparison healthy to CE
C12 Greyhound 36 fn duo comparison healthy to CE
C13 Beagle 36 m duo comparison healthy to CE
C14 Beagle 24 m duo comparison healthy to CE
C15 Beagle 48 fn duo comparison healthy to CE
C16 Beagle 60 m duo comparison healthy to CE
C17 Beagle 36 f duo comparison healthy to CE
C18 Beagle 36 m duo comparison healthy to CE
C19 Beagle 96 f duo comparison healthy to CE
C20 Beagle 12 f duo comparison healthy to CE
C21 Beagle 24 m duo comparison healthy to CE
C22 Beagle 36 m duo comparison healthy to CE
C23 Beagle 16 f duo comparison healthy to CE
C24 Beagle 32 m duo comparison healthy to CE
C25 Beagle 48 f duo comparison healthy to CE
C26 Beagle 21 f duo ex-vivo, IHC
C27 Beagle 24 f duo ex-vivo, IHC
C28 Beagle 23 f duo ex-vivo, IHC
C29 Beagle 33 f duo ex-vivo, IHC
C30 Beagle 30 m duo ex-vivo, IHC
C31 Beagle 33 m duo ex-vivo, IHC
C32 Beagle 24 f duo ex-vivo, IHC
C33 Beagle 41 f duo ex-vivo, IHC
C34 Beagle 35 f duo ex-vivo, IHC
C35 Beagle 23 f duo ex-vivo, IHC
C36 Beagle 32 f duo ex-vivo, IHC
C37 Beagle 95 f duo IHC
Most of these samples were part of a tissue archive, whereas samples from the clinical trial were collected prospectively. F = female, fn = female
neutered, m = male, mn = male neutered, IHC = immunohistochemistry, ex-vivo = ex-vivo tissue stimulation with different ligands.
doi:10.1371/journal.pone.0120779.t001
Effect of Probiotics on the Canine Intestinal Inflammasome
PLOSONE | DOI:10.1371/journal.pone.0120779 March 23, 2015 5 / 18
Expression of inflammasome-related genes in the duodenum and colon
is not altered by treatment for canine chronic enteropathy
To assess the effect of EF treatment in vivo on the inflammasome pathway in the intestine, as
well as to compare to our in-vitro and ex-vivo data, we next examined the mRNA expression of
inflammasome-related genes in duodenal and colonic samples from 12 dogs diagnosed with
CE before (visit 1) and 6 weeks into treatment (visit 2) with a hydrolyzed antigen diet (the sig-
nalment of these dogs can be found in Table 1). Clinically, these dogs showed mild to moderate
Fig 1. Amplification of NLRP1 and NLRC4 genes from canine samples. Both NLRP1 (A,C; (expected product size 363 bp) and NLRC4 (B,D; expected
product size 365 bp) expression could not be detected in cDNA (A, B), but could be in gDNA (C, D). L = hyperladder II (Bioline, UK). All labelled lanes
(exception lane 1 = empty) have been loaded with cDNA or gDNA samples, respectively. The last lane in A (lane 15) and B (lane 17) are an assay control
with GAPDH amplification from a cDNA sample (product size 194 bp).
doi:10.1371/journal.pone.0120779.g001
Fig 2. Amplification of NLRP3 from canine intestinal cDNA samples (expected product size 207 bp).
All labelled lanes have been loaded with cDNA. Lane 15 is an assay control with GAPDH on an intestinal
cDNA sample (product size 194 bp). L = hyperladder II (Bioline, UK).
doi:10.1371/journal.pone.0120779.g002
Effect of Probiotics on the Canine Intestinal Inflammasome
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disease with a CCECAI median of 4.3 (sd 1.1) before treatment. Most dogs presented with
mixed small and large intestinal signs (n = 6), 3 dogs had small intestinal diarrhea only, 2 dogs
had chronic vomiting as the main presenting complaint and 1 dog had large intestinal diarrhea
only. All of these dogs received gastroduodenoscopy and colonoscopy with multiple mucosal
pinch biopsies. Their histopathological diagnosis for the duodenum was mild to moderate lym-
phoplasmacytic infiltration (n = 9), eosinopihilic inflammation (n = 2), and mixed inflamma-
tion (n = 1). For the colon, histological diagnoses included mild lymphoplasmacytic colitis
(n = 5), normal tissue (n = 5) and eosinophilic colitis (n = 1). Histological scoring was per-
formed using the WSAVA guidelines. Here the dogs had a median total score of 3 (range 1–5)
in the duodenum and 2 (range 1–5) in the colon at the first visit. In addition to the diet, 7 of
these dogs were randomly assigned to receive Synbiotic D-C (EF and prebiotics), and 5 to re-
ceive placebo. CCECAI decreased to a mean of 1.9 (sd 1.2) for all dogs combined with no sig-
nificant difference between probiotic or placebo treatment. This decrease of clinical activity
between the two visits was highly significant (p< 0.001), confirming these dogs to be food-re-
sponsive. Median total WSAVA histology scores was 1 (range 0–8) for the duodenum and 2
(0–4) for the colon after treatment. Linear mixed modelling of WSAVA scores with “visit” as
the main effect revealed no significant difference between samples from before and after treat-
ment. The only significant change was a decrease in inflammatory score from before to after
treatment in the colon (p = 0.034), which translated into a significantly lower total colonic
score (p = 0.012).
In the duodenum, gene expression of IL-1β, IL-18, casp-1 and NLRP3 was not significantly
different between dogs with probiotic or placebo treatment. Both IL-1β and NLRP3 were ex-
pressed at much lower levels than IL-18 and casp-1. Even though gene expression of IL-18
Fig 3. Relative expression of inflammasome-related genes in canine duodenal tissue. Expression
levels from healthy control dogs (C) and dogs with chronic enteropathy (CE) were compared using Mann
Whitney U test. Data are presented as median and interquartile range.
doi:10.1371/journal.pone.0120779.g003
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seems to subjectively reduce less in Synbiotic D-C treated dogs at visit 2 (Fig. 7) compared to
the placebo group, this was not statistically significant. In general, it was observed that inflam-
masome-related genes were expressed at a much higher level in the colon than in the duode-
num (both in healthy and CE dogs; Fig. 7 & 8), which was especially the case for casp-1. There
was also no significant difference in IL-1β, IL-18 or NLRP3 gene expression before and at the
end of treatment period in the colon (Fig. 8). Using linear mixed modelling, an interaction be-
tween treatment and visit was detected for casp-1 expression in the colon (p = 0.044), but there
was no independent effect of disease status or treatment for this gene.
Discussion
In the present study, we assessed how the application of EF to ex-vivo biopsies, or given as oral
treatment, affects expression of inflammasome components in healthy dogs and dogs with CE.
Due to the absence of more suitable antibodies, this was mostly done by assessing transcription
levels using quantitative reverse-transcription PCR (qPCR), but also by IHC to assess protein
production for selected components.
Only one other study has investigated so far the inflammasome output in dogs with CE so
far. However, this was based on the assessment of the inflammatory cytokine IL-1β and the
Fig 4. Expression of inflammasome-related genes in duodenal samples stimulated with different Toll-
like receptor (TLR) ligands and Enterococcus faeciumNCIMB 10415 (EF). Endoscopic biopsies were
incubated for 5 hours with the respective stimulant. PBS = phosphate buffered saline (control), Flag = flagellin
(TLR5 ligand), Pam = Pam3CSK4 (TLR1/2 ligand), LPS = lipopolysaccharides (TLR4 ligand). Linear mixed
modelling was performed to compare data; using both “treatment” as well as “disease status” as a main
effect. IL-18 decrease in response to LPS or flagellin is different between samples from diseased and healthy
dogs, whereas the casp-1 increase seen with EF stimulation is independent of disease status. Data are
presented as median with 10–90 percentiles.* p< 0.05, ** p< 0.01.
doi:10.1371/journal.pone.0120779.g004
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PLOSONE | DOI:10.1371/journal.pone.0120779 March 23, 2015 8 / 18
Fig 5. Immunohistochemistry for canine Interleukin-1β in the canine duodenum. Purple staining denotes positive cells (VIP-staining). Columns
represent the tissue incubated with either the no-antibody control (diluents only; control serum or antibody at 1:400). Rows represent different types of
tissues. DH82 cells serve as a negative (unstimulated) and positive (stimulated with lipopolysaccharides = LPS) control tissue. Duodenum control are
samples from healthy dogs; CE = tissue from dogs with food-responsive chronic enteropathy.
doi:10.1371/journal.pone.0120779.g005
Fig 6. Averaged counts of cells staining positive for IL-1β in canine duodenal sections with immunohistochemistry. (A) Total number of cells positive
for IL-1β as assessed by immunohistochemistry in healthy dogs, dogs with chronic enteropathy before treatment (V1 = visit one before dietary intervention)
and after 6 weeks of treatment (V2 = visit two, 6 weeks into dietary intervention). (B) Number of IL-1β positive cells in the villous region. (C) Number of IL-1β
positive cells in the lamina propria. * p< 0.05, *** p< 0.001.
doi:10.1371/journal.pone.0120779.g006
Effect of Probiotics on the Canine Intestinal Inflammasome
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IL-1β receptor antagonist. No study has so far assessed different NLRs in healthy or diseased
dogs. Here, no NLRP1 mRNA expression was detected in duodenal samples from healthy and
CE dogs, which might imply that this gene does not play a major role in the innate immune
mechanisms in the canine gut. On the contrary the absence of NLRC4 mRNA expression was
not unexpected, as one other study has already described this gene as non-functional in the ca-
nine population [27]. Based on these results, we focused on the analysis of NLRP3, as at the
time of the start of the experiments, no sequences for other NLRs such as NLRP6, 8, 9 or 14
were available. NLRP3 expression was significantly lower in samples from dogs with CE com-
pared to healthy controls. This is in contrast to findings in experimental colitis in rodents,
where NLRP3 is up-regulated [20]. It is thought that inflammasome activation occurs by in-
creased permeability of the intestinal mucosal barrier, which leads to a higher bacterial load.
However, inappropriately low NLRP3 expression could also be one of the causes of intestinal
barrier instability and on-going inflammation, as NLRP3 has been shown to be important for
the maintenance of intestinal mucosal integrity [22]. Thus, whether the low NLRP3 transcript
levels seen here are a cause or result of intestinal inflammation, or simply play no role in canine
CE pathogenesis remains unclear.
Caspase-1 is the major enzyme activated by NLR stimulation. Its purpose is to cleave the
pro-forms of IL-1β and IL-18 into their active forms. Caspase-1 is hence assumed to be up-reg-
ulated on the mRNA and protein level in inflammatory conditions such as CE. The down-regu-
lation of casp-1 mRNA in this study therefore contrasts findings in human IBD [16]. However,
transcription levels do not provide information about enzyme activity levels. A casp-1 activity
Fig 7. Relative expression of inflammasome-related genes in the duodenum of 12 dogs undergoing
treatment for food-responsive chronic enteropathy. All dogs received a hydrolysed protein diet plus either
Synbiotic D-C© (Enterococcus faecium [EF] NCIMB 10415 & prebiotics) or placebo (Plac). Gene expression
was determined from endoscopic pinch biopsies before (V1 = visit one) and after 6 weeks of treatment
(V2 = visit two). Data are presented as median and interquartile range. IL = interleukin, casp-1 = caspase 1,
NLRP3 = NOD-like receptor with pyrin domain 3.
doi:10.1371/journal.pone.0120779.g007
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assay or the assessment of transcription of casp-1 subunits [28] would have been more infor-
mative, but was unfortunately not performed.
Having investigated the NLR component expression under ‘steady-state’ conditions in
healthy dogs and dogs with CE, we next investigated the effect of an EF-stimulation of duode-
nal biopsies ex-vivo. Incubation with EF increased casp-1 transcript levels compared to stimu-
lation with pure TLR ligands, but did not alter NLRP3 gene expression independent of disease
status. Stimulation with other TLR ligands showed negligible effects on mRNA levels of the in-
vestigated inflammasome components apart from IL-18. This might not be entirely unexpect-
ed, as these are not direct stimulators of the inflammasome. NLRP1 and NLRC4 have a more
select range of direct stimulators as far as known from experimental animal and human studies,
whereas NLRP3 seems to have a wider array of possible stimulatory molecules. Flagellin signals
through TLR5 and NLRC4 in humans and mice, but TLR5 gene expression was not changed in
the ex-vivo stimulated samples and NLRC4 was not investigated for reasons mentioned above
[27]. Nonetheless, increased TLR5 downstream signalling (without mRNA up-regulation)
could result in a transcription bias towards NFκB-regulated cytokines, thereby shunting the
inflammasome pathway (especially with no functional NLRC4 present), resulting in a lower
casp-1 expression and/or activity.
Transcript levels of IL-1β and IL-18 were not significantly different between healthy and
diseased dogs. This is again different to human IBD, where both IL-1β and IL-18 mRNA levels
are highly up-regulated in intestinal biopsies [13–16, 29]. However, IL-1β protein production
Fig 8. Relative expression of inflammasome-related genes in the colon of 12 dogs undergoing
treatment for food-responsive chronic enteropathy. All dogs received a hydrolysed protein diet plus either
Synbiotic D-C© (Enterococcus faecium [EF] NCIMB 10415 & prebiotics) or placebo (Plac). Gene expression
was determined from endoscopic pinch biopsies before (V1 = visit one) and after 6 weeks of treatment
(V2 = visit two). Data are presented as median and interquartile range. IL = interleukin, casp-1 = caspase 1,
NLRP3 = NOD-like receptor with pyrin domain 3.
doi:10.1371/journal.pone.0120779.g008
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as assessed by IHC was increased in the lamina propria of CE dogs examined here compared to
healthy control dogs, which could be an indication for increased casp-1 activity under certain
inflammatory circumstances. This finding is similar to findings in human pediatric IBD [30].
Maeda et al. found similar results with regards to transcription of levels of IL-1β in dogs with
CE [26]. However, these authors did not detect an increase of this cytokine’s protein levels,
which could be due to the use of different techniques used in both studies (ELISA of homoge-
nised tissue lysates versus IHC). Further disparity between mRNA and protein levels of IL-1β
could stem from the fact that we did not assess IL-1β protein expression in IECs, even though
some samples showed positive staining for IL-1β in IECs. It is known that human IECs in the
steady state do not express IL-1βmRNA, but they can produce it upon stimulation (infection,
inflammation) [31, 32]. In addition, the IL-1β IHC assay in the work presented here was per-
formed with a polyclonal antibody against the human IL-1β protein; and even though the man-
ufacturer of the antibody claimed cross-reactivity with the canine protein based on protein
sequence homology, there is some question about the antibody’s specificity in canine tissues.
Further testing of this antibody or the use of a monoclonal antibody would be needed to make
a final conclusion about IL-1β protein production in canine CE tissues.
Similarly, the fact that IL-18 mRNA expression was not different between CE and healthy
dogs has to be interpreted with caution. As mentioned in the introduction, both cytokines de-
pend on activation by cleavage through caspase-1, thus transcript levels do not have to corre-
late with protein levels in the same tissue.
Unfortunately, measurement of inflammasome-related proteins in the biopsy culture super-
natants was not successful. When assessing expression of inflammasome-related genes in sam-
ples from the clinical trial, it was interesting to note that inflammasome components are
expressed generally to a higher level in the colon compared to the duodenum. Considering the
fact that the bacterial load in the intestinal lumen is much higher in the large intestine com-
pared to the small intestine, this was not unexpected. Overall, IL-18 was found to be expressed
at much higher levels as any other cytokine investigated. This is concordant with another study
[33]. There were no differences detected in any of the investigated inflammasome components
at different time-points (before and after treatment) or with different treatments (Synbiotic
D-C vs. placebo), even though especially IL-18 gene expression seems to undergo some subjec-
tive changes between visits, especially when stimulated ex-vivo with flagellin. Several samples
from the clinical trial were also available for IHC assessment of IL-1β protein production in du-
odenal tissues. IL-1β-positive cells were found to decrease after treatment with an elimination
diet, regardless of additional treatment with probiotic or placebo. This could be due to the fact
that transcription levels of cytokines undergoing activation and possible post-translational
modifications do not have to correlate with their protein production levels.
At this stage, an important role of the NLRs and their down-stream molecules in the devel-
opment or maintenance of inflammation in canine CE cannot be excluded. Especially the re-
duction in IL-1β protein levels with dietary interventions in canine food-responsive CE seems
an interesting target for future investigations. There also is the possibility to reduce IL-18
mRNA levels with treatment in CE. Additionally, determination of casp-1 enzymatic activity
warrants further investigations.
Similarly, there is no firm evidence that probiotic treatment (ex-vivo or in-vivo) has any im-
pact on the expression of the investigated inflammasome components in intestinal tissues from
CE dogs. For ex-vivo studies, stimulation of intestinal tissues or selected intestinal cells with
compounds more tailored towards inflammasome activation or blockage might be more ap-
propriate. However, this might be improved by the selection of inflammasome-specific stimu-
lants. For the clinical trial, there was no effect of EF on inflammasome gene expression. This
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might not exclude any beneficial effect of probiotics in this setting, but different bacterial
strains, dosages or a different panel of genes to be investigated have to be considered.
Methods
Ethics statement for prospectively collected samples
Dogs with CE were recruited as part of a prospective clinical trial conducted at the Queen
Mother Hospital for Animals (Royal Veterinary College, London, UK) investigating properties
of the probiotic Enterococcus faecium NCIMB 10415 (EF). The study was performed according
to the Animal Scientific Procedures Act (ASPA approval number 70/7393) and had received
ethical approval by the Royal Veterinary College’s (RVC) Ethics and Welfare committee prior
to the start of recruitment. Samples acquired from those dogs were processed in the molecular
laboratories of the RVC’s Clinical Investigation Centre.
Control dogs consisted of Beagles from an experimental colony kept at the Justus-Liebig
University (JLU; Giessen, Germany). Regional council approval had been received for obtain-
ing fresh endoscopic intestinal biopsies from these dogs (no. 36/2011) according to the German
Protection of Animals Act.
Sourcing of samples from healthy and diseased animals used in the
study
In the first part of this study, archived intestinal endoscopic biopsy samples from client-owned
dogs with spontaneous CE (more specifically idiopathic IBD) and healthy dogs (collected as
part of an unrelated study and kept at −80°C in RNA later) were used to compare baseline
inflammasome gene expression. Clinical data or data of histological severity were unfortunately
not available for these samples at the time this study was conducted. The signalment of these
dogs can be found in Table 1. For the second part of this study (ex-vivo biopsy stimulation, see
below), fresh endoscopic intestinal biopsies were collected prospectively from dogs participat-
ing in the clinical trial mentioned above (see Table 1). Samples from these dogs were also used
to compare gene expression before and after treatment for food-responsive CE, as the trial in-
volved a second endoscopy after 6 weeks of treatment. Therapy consisted of a standardised hy-
drolyzed protein diet for all dogs (Purina Veterinary Diets HA Hypoallergenic) and either
Synbiotic D-C (EF 1 x 109 CFUs, fructo-oligosaccharides, gum Arabic; Protexin Ltd., Somerset,
UK) or placebo (maltodextran) in a double-blinded fashion. For all cases, the diagnosis of CE
was based on the presence of appropriate clinical signs (vomiting and/or diarrhoea ± weight
loss) of at least 3 weeks’ duration, exclusion of other causes of chronic gastrointestinal signs
and the presence of lymphoplasmacytic and/or eosinophilic inflammation on histopathological
examination of intestinal biopsies. Food-responsive CE was defined as improvement of clinical
signs as assessed by the canine chronic enteropathy clinical activity index (CCECAI) while fed
the standardised hydrolysed protein diet for 6 weeks.
Control dogs were deemed healthy based on the absence of clinical signs, normal physical
examination and no abnormalities on routine haematology, serum biochemistry and
intestinal histopathology.
Isolation of total RNA and Reverse transcription
Endoscopic intestinal biopsies were homogenised in 350 μl RLT lysis buffer each (Qiagen,
Manchester, UK), using 5 mm stainless steel beads (Qiagen) and the Mixer Mill MM300 tissue
grinder (Retch, Leeds, UK). Total RNA was extracted using the RNeasy micro kit (Qiagen) as
per manufacturer’s instructions, including an on-column DNAse treatment. Samples were
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eluted in 30 μl distilled water. RNA quantity and quality was assessed using the Eukaryote
Total RNA Nano chip with the Agilent BioAnalyzer (Agilent Technologies, Wokingham, UK),
and only RNA with a RIN number of> 6 was used. Using this assay, no DNA contamination
could be detected in any sample.
Reverse transcription was performed using the iScript cDNA synthesis kit (Bio-Rad, Hemel
Hampstead, UK), which uses a mixture of oligo-dT and random nonamer primers.
Standard polymerase chain reaction to detect presence of NLR mRNA
Polymerase chain reaction (PCR) was performed using the Immolase taq polymerase (Bioline,
London, UK) as outlined by the manufacturers. Reactions were performed in a final volume of
25 μl with 1 μl of template, 800 pmol of primers and 2.5 mMMgCl2. Cycling was performed at
the following conditions: 95°C for 7 min for enzyme activation, then 35 cycles of 95°C for 30
sec (denaturation), annealing for 30 seconds at 55°C, 72°C for 1 minute (extension) and a final
extension step at 72°C for 7 minutes. Primers were based on published gene sequences sourced
from Genbank (http://www.ncbi.nlm.nih.gov/genbank/) and/or ENSEMBL (www.ensembl.
org) servers (versions 68–70) (see Table 2). They were designed using the Primer3 online tool
(frodo.wi.mit.edu/) with the default specifications and manufactured by Eurofins MWGOper-
on (Ebersberg, Germany). Primer sequences were checked for target specificity by using Basic
Logic Alignment Search Tool (BLAST; http://blast.ncbi.nlm.nih.gov/Blast.cgi). PCR products
were visualised on a 1.5% agarose gel.
Reverse-transcriptase quantitative PCR for the detection of
inflammasome-related gene expression
To obtain positive controls suitable for subsequent quantitative PCR (qPCR) analysis, parts of
the canine sequences for the genes of interest and 3 reference genes were cloned as described
previously [34]. These plasmids were used in a 10-fold dilution (107 molecules μl−1 to 101
molecules μl−1) to create a qPCR standard curve for each gene and run and to assess assay effi-
ciency. Each qPCR reaction was performed in 20 μl, contained 200 nM of each primer and 1 μl
of cDNA in addition to SsoFast Evagreen Supermix (Bio-Rad). Characteristics of the primers
used can be found in Table 2. Cycling conditions consisted of an enzyme activation step at
95°C for 30 seconds, followed by 40 cycles of 95°C for 10 seconds, annealing at 55°C for 10 sec-
onds and elongation at 65°C for 10 seconds. An additional 5 seconds melting step was included
before each plate read depending on the melting curve analysis of the respective PCR products
(to melt primer dimers). Each reaction was carried out in triplicate. Melting curves were gener-
ated for each run to ensure a single amplicon had been produced.
Gene expression was quantified by averaging the triplicate absolute gene copy number for
each biological sample for all genes, following normalisation of the expression of each target
gene to the geometric mean of the three reference genes (glyceraldehyde 3-phosphate
Table 2. Internal primers used to amplify parts of genes connected to the inflammasome.
Gene product size Forward Reverse Accession number
Caspase-1 253 CGACAGACAG CTGGACACAT ATCTGGGCTTT CACATCTGG NM_001003125.1
IL-1 beta 440 GCAGTACCCG AACTCACCAG ACATTTTCCCC ATTGAGGTG NM_001037971.1
IL-18 240 GAGGATATGC CCGATTCTGA ATCATGGCCTG GAACACTTC XM_005619483.1
NLRC4 365 TGAGCAGCAG TGTTTTCACC TGGCTTCCATA TCCTCCCTA NC_006599.2
NLRP1 363 CCTCTTTGGC CTTCTGAGTG CTGAACAGAGC CACACTGGA XM_00546567.4
NLRP3 207 GCAATGCTCT TGGAGACACA AGAGCAGCATG ACCCCTAGA XM_00843284.2
doi:10.1371/journal.pone.0120779.t002
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dehydrogenase [GAPDH], TATA-box binding protein [TBP], succinate dehydrogenase com-
plex subunit A [SDHA]), as described recently [34, 35]. These genes have been reported to be
most stable in canine duodenal tissue [36], and a minimum of 3 reference genes was selected to
adhere to the MIQE guidelines [37].
Ex-vivo stimulation of duodenal biopsies with TLR ligands and
Enterococcus faecium
Ex-vivo culture of duodenal biopsies was performed using a previously described protocol [38]
with minor modifications: Eight duodenal pinch biopsies obtained during duodenoscopy were
immediately transferred into ice cold culture medium (RPMI 1640 + glutamine, Gibco, Paisley,
UK) with 100 U ml−1 penicillin and 100 μg ml−1 streptomycin (PAA, Somerset, UK) and care-
fully rinsed by decanting 3 times. Penicillin/ streptomycin were added in order to control the
microbiota attached to the samples, but as soon as probiotic bacteria were added, RPMI medi-
um without antibiotic additives was used. Biopsies were carefully transferred in pairs to a well
of a 24-well flat-bottomed plate (Nunc) holding 900 μl of medium. One-hundred μl of one of
the different bacterial stimulants (see below) were added. This included Toll-like receptor
(TLR) ligands (Invivogen, San Diego, USA) to simulate stimulation with well-defined single
bacterial ligands, as well as live cultures of EF. TLR ligands were added to reach the following
final concentrations (as determined by a pilot study; data not shown): Lipopolysaccharide
(LPS; Escherichia coli 0111:B4; 1 ng ml−1, TLR4 ligand), Pam3CSK4 (100 ng ml
−1; TLR1/2 li-
gand) and recombinant flagellin from Salmonella typhimurium (1 μg ml−1; TLR5 ligand). EF
was used at a concentration of 1 x 107 cfu ml−1. PBS was used as a negative control. Plates were
incubated for 5 hours at 37°C and 5% CO2. Biopsies were then transferred to 1.8 ml cryotubes
holding 1 ml of RNA later (Ambion, Huntingdon, UK), kept at 4°C for 24 hours and trans-
ferred to −80°C for storage until further use. Culture supernatants were harvested, aliquoted
and stored at −20°C until further use.
Immunohistochemistry for Interleukin-1β
Slides were prepared from duodenal samples from healthy and CE dogs from formalin-fixed,
paraffin-embedded tissue blocks originally created as part of the routine histopathological as-
sessment. Slides were deparaffinised using histology grade xylene (Sigma-Aldrich, Dorset, UK)
for 3 x 5 min and rehydrated using descending concentrations (100%, 70%, 50%, 30%) of mo-
lecular grade ethanol (Sigma-Aldrich) for 3 min each. Slides were then rinsed for 5 min in tap
water. Heat-induced antigen retrieval was performed in 0.01 M sodium citrate, pH6 (“antigen
unmasking solution low pH”, Vectorlabs, Peterborough, UK) using a standard 800 Wmicro-
wave on full power for a total of 13 minutes. From here on, a washing step was performed in-
between each incubation step by rocking the slides gently in a tray holding 250 ml of wash buff-
er (1 X TBS [Fisher Scientific, Loughborough, UK] with 0.1% Tween 20 [Sigma-Aldrich]).
Blocking endogenous peroxidase activity was performed using 0.3% hydrogen peroxide
(Sigma-Aldrich) in methanol (Sigma-Aldrich) for 30 min at room temperature. Protein block-
ing was performed using 2.5% horse serum (Vectorlabs) with 1% bovine serum albumin
(Sigma-Aldrich) for 1 h at room temperature. After incubation with the protein block, slides
were not washed, but the liquid only tipped off. The primary antibody, a rabbit-raised poly-
clonal IgG antibody against a 17 kDa recombinant peptide from the human IL-1β protein (the
cleavage site generated by caspase-1; cat# ab34837, Abcam, Cambridge, UK), was applied to
the slides immediately at a concentration of 1:400 (diluted in 1X TBS + 1% horse serum + 0.1%
Tween 20 + 0.1% Triton X-100 [Vectorlabs]). Incubation with the primary antibody was per-
formed for 6 hours at 4°C. The ImmPRESS polymer-based horse-radish peroxidase kit
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(Vectorlabs) was used for detection of the target as by the manufacturer’s instructions: Sections
were incubated with the ImmPRESS anti-rabbit reagent for 30 minutes at room temperature.
The substrate used was Very Intense Purple (VIP; Vectorlabs) as instructed by the manufactur-
er: slides were incubated with the freshly made substrate solution for 2 minutes, and then
rinsed in tap water for 5 minutes. Counterstaining was performed with haematoxylin for 5–7
seconds, followed by rinsing in tap water and dehydration using ascending concentrations of
ethanol (reverse order as for the rehydration above). Slides were mounted with Immumount
(Vectorlabs) and covered with a cover slip. Slides sine 1° antibody and slides where the 1° anti-
body was substituted with normal rabbit serum (1:1000; Vectorlabs) were included simulta-
neously as controls. Positive controls included slides from pelleted DH82 cells (a canine
macrophage/ monocyte cell line) which had previously been stimulated with 1 μg/ml LPS for 3
hours to provoke IL-1β production; as well as unstimulated pelleted DH82 cells as negative tis-
sue controls (see Fig. 5).
Statistical analyses
Statistical analysis was done using IBM SPSS statistics version 19.0. To compare gene expres-
sion data between healthy and diseased duodenal tissue at baseline, Mann-Whitney U test was
performed. To assess the effect of different stimulations in the ex-vivo assay between healthy
and diseased samples, linear mixed modelling with “treatment” and “disease status” as main ef-
fects was performed (hence all ex-vivo treatments could be compared to each other as well as
between samples from dogs with or without disease). A similar approach was taken for the
evaluation of differences in gene expression before and during treatment for CE, with probiotic
or placebo “treatment” as well as time of visit (visit 1 = before dietary treatment; visit 2 = after
6 weeks of dietary treatment) set as main effects. ELISA data from ex-vivo culture supernatants
were analysed using one-way ANOVA. Finally, cell counts from immunohistochemistry
(healthy dogs vs. CE dogs before treatment vs. CE dogs after treatment) were compared using
Kruskall-Wallis test.
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